After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Four years ago, a biotech company presented data so powerful it made scientists cry.
Speaking to a packed room at an

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up